⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Official Title: A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer

Study ID: NCT00477529

Interventions

ABI-008

Study Description

Brief Summary: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.

Detailed Description: Detailed description not necessary.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

Nebraska Methodist Hospital, Omaha, Nebraska, United States

University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Contact Details

Name: John C Araujo, MD

Affiliation: M.D. Anderson Cancer Center

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: